BACKGROUND: This study aimed to identify prognostic factors for outcome in Tunisian patients with nonmetastatic inflammatory breast cancer (IBC) receiving multimodality therapy. PATIENTS AND METHODS: From 1994 to 2000, 100 patients with nonmetastatic IBC were reviewed. Patients underwent neo-adjuvant chemotherapy including anthracyclines (99%), then mastectomy (93%) when feasible, radiotherapy (83%) and adjuvant chemotherapy (84%). Sixty patients (60%) had hormone therapy. RESULTS: Median age at diagnosis was 44 years (range 23-71). Seventy patients had premenopausal status (70%). Ten cases occurred during pregnancy (10%). Body mass index indicated overweight or obesity in 76 patients (76%). After neo-adjuvant chemotherapy, pathologic complete response (pCR) rate was 20%. Median time of follow-up for surviving patients was 44 months. Median progression-free survival (PFS) was 19 months and overall survival (OS) 30 months. Factors associated with improved survival were no pregnancy (P = 0.0095), estrogen receptor positivity (P = 0.028), tumor size <5 cm (P = 0.021), clinical complete response (cCR) (P = 0.022), pCR (P = 0.011), negative nodes (P = 0.053) and hormone therapy (P < 0.001). In multivariate analysis, cCR, negative nodes and hormone therapy were independently associated with better OS and PFS. Factors predictive to pCR were age >45 years, negative nodes and cCR. CONCLUSIONS: Tunisian patients with IBC have particular epidemiologic characteristics, with earlier disease and context of overweight and obesity, but prognostic factors are similar to those reported in the literature. Hormone therapy seems to improve patient outcome.
BACKGROUND: This study aimed to identify prognostic factors for outcome in Tunisian patients with nonmetastatic inflammatory breast cancer (IBC) receiving multimodality therapy. PATIENTS AND METHODS: From 1994 to 2000, 100 patients with nonmetastatic IBC were reviewed. Patients underwent neo-adjuvant chemotherapy including anthracyclines (99%), then mastectomy (93%) when feasible, radiotherapy (83%) and adjuvant chemotherapy (84%). Sixty patients (60%) had hormone therapy. RESULTS: Median age at diagnosis was 44 years (range 23-71). Seventy patients had premenopausal status (70%). Ten cases occurred during pregnancy (10%). Body mass index indicated overweight or obesity in 76 patients (76%). After neo-adjuvant chemotherapy, pathologic complete response (pCR) rate was 20%. Median time of follow-up for surviving patients was 44 months. Median progression-free survival (PFS) was 19 months and overall survival (OS) 30 months. Factors associated with improved survival were no pregnancy (P = 0.0095), estrogen receptor positivity (P = 0.028), tumor size <5 cm (P = 0.021), clinical complete response (cCR) (P = 0.022), pCR (P = 0.011), negative nodes (P = 0.053) and hormone therapy (P < 0.001). In multivariate analysis, cCR, negative nodes and hormone therapy were independently associated with better OS and PFS. Factors predictive to pCR were age >45 years, negative nodes and cCR. CONCLUSIONS: Tunisian patients with IBC have particular epidemiologic characteristics, with earlier disease and context of overweight and obesity, but prognostic factors are similar to those reported in the literature. Hormone therapy seems to improve patient outcome.
Authors: Nabila Chaher; Hugo Arias-Pulido; Nadija Terki; Clifford Qualls; Kamel Bouzid; Claire Verschraegen; Anne Marie Wallace; Melanie Royce Journal: Breast Cancer Res Treat Date: 2011-03-01 Impact factor: 4.872
Authors: Dora Il'yasova; Sharareh Siamakpour-Reihani; Igor Akushevich; Lucy Akushevich; Neil Spector; Joellen Schildkraut Journal: Breast Cancer Res Treat Date: 2011-08-18 Impact factor: 4.872
Authors: Catherine Schairer; Ahmed Hablas; Ibrahim AbdelBar Seif Eldein; Rabab Gaafar; Henda Rais; Amel Mezlini; Farhat Ben Ayed; Wided Ben Ayoub; Abdellatif Benider; Ali Tahri; Mouna Khouchani; Dalia Aboulazm; Mehdi Karkouri; Saad Eissa; Ruth M Pfeiffer; Shahinaz M Gadalla; Sandra M Swain; Sofia D Merajver; Linda Morris Brown; Amr S Soliman Journal: Breast Cancer Res Treat Date: 2019-04-22 Impact factor: 4.872
Authors: D S M Chan; A R Vieira; D Aune; E V Bandera; D C Greenwood; A McTiernan; D Navarro Rosenblatt; I Thune; R Vieira; T Norat Journal: Ann Oncol Date: 2014-04-27 Impact factor: 32.976